Detection of influenza B lineages from 2001 to 2013 in a tertiary hospital in the city of São Paulo, Brazil

Ana Helena Perosa, Celso Granato, Nancy Bellei

Universidade Federal de São Paulo, Departamento de Medicina, Laboratório de Virologia Clínica, Disciplina de Infectologia, São Paulo, SP, Brasil

Two antigenically distinct lineages of influenza B viruses, the Victoria-like and Yamagata-like strains, currently circulate among humans. Surveillance from United States of America and Europe over the last 10 years showed that the chance of a correct matching between vaccine and the circulating lineage had been 50%. We investigated influenza B infection in different patient groups (asymptomatic, general community, with comorbidities and hospitalised) attended at a tertiary hospital in the city of São Paulo, Brazil between 2001-2013. All samples were screened for influenza B virus by one-step real-time reverse transcription-polymerase chain reaction. From 2,992 respiratory samples collected, 114 (3.8%) tested positive for influenza B. Teenagers (13-18 years) presented the highest rate of 18.5% (odds ratio 22.87, 95% confidence interval 2.90-180.66, p < 0.001). One hundred nine samples could be characterised: 50 were Yamagata-like and 59 were Victoria-like strains. Mismatching between the vaccine and predominant circulating strain was observed in 2002 and 2013 seasons. Based on data collected during a period of 12 years, we found that influenza B was more frequent in teenagers. Co-circulation of both lineages and mismatch with the vaccine strain can occur. Our data highlighted the importance of quadrivalent vaccines and future analysis of the age groups included in vaccination programs.

Key words: influenza B lineages - influenza vaccine - epidemiology - respiratory infection

Influenza infections in humans can be caused by type A and type B viruses. Influenza A is responsible for the pandemics and the majority of seasonal infections and influenza B incidence can vary between seasons. Influenza B infections are common in children and young adults and the rates of hospitalisations, pneumonia and deaths among children infected with influenza B are similar to those for influenza A (Gutiérrez-Pizarrya et al. 2012).

Influenza B can be classified into two antigenically distinct lineages, B/Victoria/02/87-like and B/Yamagata/16/88-like, based on divergence in the HA1 domain of the viral haemagglutinin gene, and this difference is responsible for the lack of antigenic cross reaction between lineages. Reference laboratories have differentiated the lineages by haemagglutination-inhibition testing, which is a time-consuming technique that requires virus isolation. These two lineages currently circulate among humans since 1983 (Rota et al. 1990). Influenza B evolution is characterised by a continuous turnover of lineages and the match between circulating and vaccine strains vary annually (Chen & Holmes 2008). In Brazil, the current influenza vaccine distributed by the National Immunisation Program to high-risk groups for influenza complications contains only one influenza B lineage.

Surveillance from 2001-2011 in the United States of America and Europe showed that the chance of a correct matching between vaccine and circulating influenza B lineages was 50% (Ambrose & Levin 2012). Consequently, the influenza vaccination was less effective during mismatched seasons. Information about the circulation of these lineages is important to assess the need for a quadrivalent influenza vaccine. The objective of this study was to describe the influenza B circulation in different patient groups from a tertiary hospital of the largest city in the Southern Hemisphere from 2001-2013 and the lineage differentiation of this virus using a sensitive and lineage specific real-time reverse transcription-polymerase chain reaction (RT-PCR) method.

SUBJECTS, MATERIALS AND METHODS

Study design and sample collection - During the 12-year study, respiratory samples were collected from subjects with different risk for influenza acquisition. We evaluated 2,992 samples (1,926 nasopharyngeal swabs, 871 nasal washes and 195 nasopharyngeal aspirates) collected between June 2001-October 2013 (except 2006) from patients attended at primary care health service in ambulatory or specific units of a tertiary hospital (a referral hospital with basic services and specific care) from the city of São Paulo, Brazil. Each of these health services had a variable flow of sampling, which resulted in collections of different patient groups, unevenly distributed throughout the study period. Samples were classified into six patient groups: (i) emergency care: outpatients from the general community (adults, children and healthcare workers) with acute respiratory infection (ARI), collected from 2001-2005 and 2008-2013; (ii) kidney transplant (KT) recipients: adults outpatients with ARI recruited during routine visits, collected from
Influenza B lineages • Ana Helena Perosa et al.

2002-2004; (iii) high-risk children: children with heart and/or lung diseases and/or premature birth with ARI recruited during routine visits, collected from 2005-2008; (iv) human immunodeficiency virus (HIV)-positive patients: adults outpatients with ARI or asymptomatic recruited once a week during scheduled routine visits during influenza epidemic period, collected from 2010-2013; (v) patients in a haematopoietic stem cell transplant (HSCT) program: hospitalised adults with ARI or contact with a symptomatic patient, collected from 2004-2013; (vi) hospitalised patients: inpatients (adults and children) with severe acute respiratory infection (SARI), suspected of 2009 H1N1 influenza A infection, collected from 2009 to 2013.

Laboratory methods - Nucleic acid was extracted from 140 µL aliquots that had been stored at -80°C, using the QIAmp Viral RNA Extraction Kit (Qiagen, Germany), according to the manufacturer’s recommendations. The influenza B one-step real-time RT-PCR was performed using primers for the nonstructural gene (forward: 5’-TCCTCAACTCACTCTTCGAGCG-3’; reverse: 5’-CGGTGCTCTTGACCAAATTGG-3’; probe: 5’-VIC-CCAATTCGAGCAGCTGAAACTGCGGTG-MGB-3’) previously described by Selvaraju and Selvarangan (2010). Reaction mixtures (25 µL) were prepared using the AgPath-ID™ One-Step RT-PCR Kit (Ambion) and contained final concentrations: 1x RT-PCR buffer, 1x RT-PCR enzyme mix, 0.8 µM of each primer, 0.2 µM probe, nuclease-free water and 5 µL of nucleic acid. Amplification was performed on ABI 7500 Real-time PCR System (Applied Biosystems) with the following cycling conditions: 50ºC for 10 min, 95ºC for 10 min and 95ºC for 15 s followed by 55ºC for 30 s (45 cycles). Each specimen was also tested for the human ribonuclease P gene (constitutive gene) as an internal control (CDC 2009).

Influenza B positive samples were tested to identify the lineages using a single one step real-time RT-PCR with one pair of primers (forward: 5’- ACCCTACAR-AMTTGGAACYTCAGG-3’; reverse: 5’-ACAGCCCAAGCCATTGTG-3’) and two probes with different colour labels: 5’-FAM-AATCCGMYTTACTGGTAG-MGB-3’ (for identification of Yamagata lineage) and 5’-VIC-ATCCGTTTCCATTGGTAAMGB-3’ (for identification of Victoria lineage) previously described by Biere et al. (2010). Reaction mixtures (25 µL) were prepared using the AgPath-ID™ One-Step RT-PCR Kit (Ambion) and contained final concentrations: 1x RT-PCR buffer, 1x RT-PCR enzyme mix, 0.9 µM of forward primer, 0.6 µM of reverse primer, 0.15 µM of each probe, nuclease-free water and 5 µL of nucleic acid. Amplification was performed on ABI 7500 Real-time PCR System (Applied Biosystems) with the following cycling conditions: 50ºC for 10 min, 95ºC for 10 min and 95ºC for 15 s followed by 60ºC for 30 s (50 cycles).

Data analysis - We considered as “predominated year” when Victoria or Yamagata lineages circulated in over 80% of the specimens. Additionally, each influenza season was categorised as matched or mismatched after comparing the most commonly circulating influenza B lineage and the vaccine component distributed by the Brazilian Health Office.

Statistical analysis consisted of chi-squared test for the comparison of categorical values, with a significance level of p < 0.05. Results are presented as odds ratios and the respective 95% confidence intervals (CI). All data were analysed using the Statistical Package for Social Sciences v.18.0.0 (SPSS IBM).

RESULTS

We analysed 2,992 respiratory samples and the median age of all studied patients was 28 ± 22 years (range: 14 days-91 years); 284 (9.5%) patients had been vaccinated against influenza in the same year of sample collection. The median age and standard deviation of each patient group was: 24 years (± 18) for emergency care,
TABLE I  
Demographic and epidemiological characteristics of subjects

<table>
<thead>
<tr>
<th>Samples tested</th>
<th>Influenza B</th>
<th>Odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>n (%)</td>
<td>p</td>
</tr>
</tbody>
</table>

**Patient groups**
- Emergency care: 1,468 samples, 76 (5.2%) influenza B, p = 0.002, odds ratio 10.59 (1.47-76.60)
- KT: 251 samples, 10 (4%) influenza B, p = 8.0 (1.02-63.17)
- HSCT: 255 samples, 7 (2.7%) influenza B, p = 5.48 (0.67-44.88)
- HIV: 139 samples, 2 (1.4%) influenza B, p = 2.83 (0.25-31.55)
- Hospitalised: 684 samples, 18 (2.6%) influenza B, p = 5.24 (0.70-39.53)
- High-risk children: 195 samples, 1 (0.5%) influenza B, p = 1 (Ref)

**Vaccine**
- Yes: 284 samples, 8 (2.8%) influenza B, p = 0.359 -
- No or not informed: 2,708 samples, 106 (3.9%) influenza B, p = -

**Symptoms**
- ARI: 1,908 samples, 93 (4.9%) influenza B, p = < 0.001, odds ratio 6.78 (2.14-21.52)
- SARI: 684 samples, 18 (2.6%) influenza B, p = 3.58 (1.05-12.22)
- Asymptomatic: 400 samples, 3 (0.75%) influenza B, p = 1 (Ref)

* a: significant at p < 0.05; ARI: acute respiratory infection; CI: confidence interval; HIV: human immunodeficiency virus (positive patients); HSCT: haematopoietic stem cell transplant patients; KT: kidney transplant; SARI: severe ARI.

TABLE II  
Influenza B detection by age groups

<table>
<thead>
<tr>
<th>Age groups (years)</th>
<th>Samples tested n</th>
<th>Influenza B n (%)</th>
<th>Odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-12</td>
<td>1,075</td>
<td>37 (3.4)</td>
<td>3.60 (0.49-26.52)</td>
</tr>
<tr>
<td>13-18</td>
<td>65</td>
<td>12 (18.5)</td>
<td>22.87 (2.90-180.66)</td>
</tr>
<tr>
<td>19-65</td>
<td>1,750</td>
<td>64 (3.6)</td>
<td>3.8 (0.53-27.92)</td>
</tr>
<tr>
<td>&gt; 65</td>
<td>102</td>
<td>1 (1)</td>
<td>1 (Ref)</td>
</tr>
</tbody>
</table>

* a: significant at p < 0.05; CI: confidence interval; p < 0.001.

TABLE III  
Influenza B detection and lineage identification by year

<table>
<thead>
<tr>
<th>Year</th>
<th>Samples tested (n = 2,992)</th>
<th>Influenza B (%)</th>
<th>Yamagata-like (%)</th>
<th>Victoria-like (%)</th>
<th>Vaccine lineage</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>74</td>
<td>12 (16.2)</td>
<td>11 (100)</td>
<td>-</td>
<td>Yamagata</td>
</tr>
<tr>
<td>2002</td>
<td>212</td>
<td>21 (9.9)</td>
<td>5 (25)</td>
<td>15 (75)</td>
<td>Yamagata</td>
</tr>
<tr>
<td>2003</td>
<td>130</td>
<td>0</td>
<td>-</td>
<td>-</td>
<td>Victoria</td>
</tr>
<tr>
<td>2004</td>
<td>190</td>
<td>7 (3.7)</td>
<td>-</td>
<td>6 (100)</td>
<td>Victoria</td>
</tr>
<tr>
<td>2005</td>
<td>73</td>
<td>1 (1.4)</td>
<td>1 (100)</td>
<td>-</td>
<td>Yamagata</td>
</tr>
<tr>
<td>2007</td>
<td>32</td>
<td>0</td>
<td>-</td>
<td>-</td>
<td>Victoria</td>
</tr>
<tr>
<td>2008</td>
<td>370</td>
<td>17 (4.6)</td>
<td>9 (56)</td>
<td>7 (44)</td>
<td>Yamagata</td>
</tr>
<tr>
<td>2009</td>
<td>586</td>
<td>5 (0.8)</td>
<td>5 (100)</td>
<td>-</td>
<td>Yamagata</td>
</tr>
<tr>
<td>2010</td>
<td>438</td>
<td>20 (4.7)</td>
<td>19 (95)</td>
<td>1 (5)</td>
<td>-</td>
</tr>
<tr>
<td>2011</td>
<td>435</td>
<td>24 (5.5)</td>
<td>-</td>
<td>24 (100)</td>
<td>Victoria</td>
</tr>
<tr>
<td>2012</td>
<td>207</td>
<td>1 (0.5)</td>
<td>-</td>
<td>1 (100)</td>
<td>Victoria</td>
</tr>
<tr>
<td>2013</td>
<td>245</td>
<td>6 (2.4)</td>
<td>-</td>
<td>5 (100)</td>
<td>Yamagata</td>
</tr>
</tbody>
</table>

* a: there was no sampling during 2006; b: vaccine recommendation for Southern Hemisphere. Vaccine distributed in Brazil during 2010 contained only the influenza A(H1N1)pdm09 strain.
In three of the 12 years of study, the predominant circulating lineage was different from that selected for vaccine composition. In 2002 and 2013, the influenza B component of the Southern Hemisphere influenza vaccine was of the B/Yamagata lineage, but more than 70% of the circulating viruses were identified as the B/Victoria lineage. Data from the Brazilian National Surveillance demonstrated that the Victoria lineage reappeared in southern and southeastern Brazil during 2002 and predominated during the 2003, 2004, 2007, 2011 and 2012 influenza seasons. In contrast, the co-circulation of the two lineages was demonstrated during the 2002, 2005, 2006 and 2008 seasons (Motta et al. 2006, Paiva et al. 2013). In 2010, the B/Victoria lineage was recommended for the Southern Hemisphere vaccine; however, the vaccine that was distributed in Brazil was monovalent and included only the influenza A(H1N1)pdm09 strain. Data from international surveillance showed that, during the 2007-2008 influenza seasons, only 2% of the influenza B viruses were identified as belonging to the B/Victoria lineage that was the influenza B component for the 2007-2008 Northern Hemisphere influenza vaccine (CDC 2008). During the 2011-2012 seasons in Taiwan, there was a large influenza B epidemic caused by a Yamagata lineage, but the influenza B vaccine component was from the Victoria lineage (Lo et al. 2013).

Studies have shown that influenza-related direct and indirect costs were higher during the mismatched than matched seasons (Karve et al. 2013). Inclusion of the correct influenza B lineage in trivalent vaccines is a challenge; therefore, public health centres have analysed the possibility of reformulating the annual influenza vaccine to include both lineages of influenza B viruses in a quadrivalent vaccine. Clinical trials with quadrivalent vaccines showed improved protection in children, were as safe and immunogenic as trivalent vaccines and could be an alternative to influenza vaccination (Dowchowske et al. 2013, Greenberg et al. 2013).

A limitation of our study is the small number of positive samples that were analysed in some years, which may not represent the real proportion of circulating viruses. We were also not able to assess the real impact of matched and mismatched seasons because the distribution of age groups was not homogeneous between studied years.

On the basis of data collected during a period of 12 years in a tertiary hospital of the largest city in the Southern Hemisphere, we found that teenagers were the most affected by influenza B infections, raising questions about which age groups should be included in vaccination programs. Co-circulation of both lineages was not common, but occurred recently. Furthermore, mismatch with the vaccine strain should be evaluated to support the introduction of a quadrivalent vaccine.

REFERENCES


